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Interferon is a monotherapy or combination therapy an-
tiviral drug for patients suffering from chronic hepatitis 
C. Certain ocular complications from interferon therapy 
have been reported, however, such as cotton wool spots 
[1-7], retinal hemorrhages [1-7], and optic neuropathy [8], 
among others. By pegylation of polyethylene glycol (PEG) 
to interferon, pharmacokinetially improved pegylated 
interferon has a larger molecular weight and a longer half 
life in the serum than non-pegylated interferon [3], which 
increases the efficacy of the drug for chronic hepatitis C 
patients. Non-pegylated interferon has a 12% to 16% clear-
ance rate in the serum, whereas the 50% to 60% clearance 
rate of pegylated interferon makes it safer for long-term 
use by patients [3]. Even though pegyalted interferon is a 
more effective drug for chronic hepatitis C patients, to our 
knowledge there are no existing reports or studies about 
pegylated interferon-associated ocular complications such 
as interferon-associated retinopathy. To bring the issue 
to light, this study reports a case of pegylated interferon-
associated acute and irreversible severe retinopathy in a 
patient with chronic hepatitis C.
Case Report
A 32-year-old female was diagnosed with chronic hepa-
titis C (grade 3/4, stage 2/4, genotype 2a/c) in February of 
2007. She underwent treatment with pegylated interferon-
α2b 80 micrograms and ribavirin combination therapy for 
5 months (from February of 2007 until July of 2007). She 
was also treated with subcutaneous insulin injections for a 
previous condition of pregnant diabetic mellitus diagnosed 
seven years before. She was first referred to ophthalmol-
ogy in February of 2007 for a diabetic retinopathy exami-
nation. Her vision was 0.6 in both eyes, and intraocular 
pressure was 11 mmHg in the right eye and 12 mmHg in 
the left eye. Fundus examination found moderate nonpro-
liferative diabetic retinopathy (NPDR) in the right eye and 
mild NPDR in the left eye. Accordingly, a follow-up visit 
to check her eyes was scheduled for six months later. She 
felt visual blurring two months later, and we referred to a 
past ophthalmologic exam in June of 2007. At that time, 
her best corrected visual acuity was 0.04 in both eyes. 
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This paper reports a case of pegylated interferon-associated retinopathy in a patient with chronic hepatitis C. A 
32-year-old female with chronic hepatitis C undergoing pegylated interferon and ribavirin combination therapy 
complained of visual blurring. Features of interferon-associated retinopathy, including ocular complications such 
as cotton wool spots, retinal hemorrhages, macular edema, and branch retinal vein occlusion, were found in 
the fundus of both of her eyes. Pegylated interferon combination therapy was stopped, and the retinopathy of 
the patient was treated with intravitreal bevacizumab injections and panretinal photocoagulations. This case 
shows that pharmacokinetically improved pegylated interferon has ocular complications for patients with chronic 
hepatitis C. Accordingly, patients undergoing pegylated interferon treatment for hepatitis C need regular eye 
examinations for protection of their vision.
Key Words: Chronic hepatitis C, Interferon-associated retinopathy, Ocular vision, Pegyalted interferon
Received: May 19, 2008    Accepted: August 4, 2010
Corresponding Author: Min Chul Shin, MD, PhD. Department of Oph-
thalmology, Chuncheon Sacred Heart Hospital, Hallym University Col-
lege of Medicine, #77 Sakju-ro, Chuncheon 200-704, Korea. Tel: 82-33-
240-5176, Fax: 82-33-241-8063, E-mail: mcshin@hallym.ac.kr148
Korean J Ophthalmol Vol.26, No.2, 2012
Previous fundoscopy revealed retinal hemorrhages, cot-
ton wool spots, macular edema, and new vessels elsewhere 
(NVE) in both eyes (Fig. 1). The pegylated interferon and 
ribavirin combination therapy was stopped, and the patient 
was treated with intravitreal 0.05 mL bevacizumab (Avas-
tin) injections. Panretinal photocoagulations were added.
After completion of treatment, the patient’s retinal hem-
orrhages, cotton wool spots, and macular edema improved 
(Fig. 2). The retinal non-perfusion areas (Figs. 3 and 4) and 
the best corrected visual acuity of the patient did not im-
prove. As of June, we began regular ophthalmic examina-
tion of her eyes every other week.
Discussion
Standard interferon therapy in chronic hepatitis C 
patients causes various ocular complications, including 
branch retinal vein occlusion [2], subconjunctival hemor-
rhages [5], visual blurring, papilledema [8], neovascular 
glaucoma, and retinal detachment [9], among others. The 
most common among the ocular complications are reti-
nopathy-parapapillary retinal hemorrhages at the posterior 
pole, and cotton wool spots [1,2,4]. These features of reti-
nopathy occur in approximately 18% to 86% of alpha in-
terferon-treated chronic hepatitis C patients [1]. A study by 
Jain et al. [4] has reported that these features of retinopathy 
may occur between 4 to 12 weeks after the start of inter-
feron and ribavirin combination therapy, and will regress 
within 4 to 12 weeks after therapy stops. The pathogenesis 
of these features of retinopathy is unknown, however, the 
hypothesis that interferon interferes with retinal microcir-
culations is persuasive [7]. In this respect, interferon treat-
Fig. 1. Retinal hemorrhages, cotton wool spots, macular edema, and new vessels were found in both of the patient’s eyes.
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Fig. 2. (A,B) After intravitreal bevacizumab injections and panretinal photocoagulations, the cotton wool spots and retinal hemorrhages 
regressed, but the new vessels remained.
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ment for patients with abnormal microcirculation diseases, 
such as diabetic mellitus or hypertension, has a very high 
risk of causing interferon-associated ocular complications 
[6,7].
The patient in this case, due to previous diagnosis of dia-
betic mellitus, belonged to a high-risk group for interferon-
associated ocular complications. The patient presented 
with retinal hemorrhages, cotton wool spots, macular 
edema, and retinal ischemic changes in both of her eyes. 
These ocular complications progress more acutely and 
severely than the progression of complications in a state of 
pre-pegylated interferon treatment, and the patient’s vision 
decreased irreversibly. 
Usually, interferon-treated patients have reversible 
interferon-associated retinopathy [1-7]. Cases of severe, 
irreversible visual impairment are very rare [10]. Chronic 
hepatitis C patients must undergo examination of their 
eyes before interferon treatment begins, and they must fol-
low up with a second exam within three months of starting 
treatment. Particularly for high-risk patients with hyper-
Fig. 4. At the late arteriovenous 
phase (A,B) and mid-venous 
phase (C,D), new vessels and 
non-perfused areas progressed.
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Fig. 3. At the late arteriovenous 
phase (A,B), many microaneu-
rys and new vessels were found. 
At the mid-venous phase, non-
perfusion was more severe in 
the left eye (D) than in the right 
eye (C).
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tension or diabetes mellitus, not only are regular follow-
up examinations very important, but also stopping the 
interferon treatment at the right time is critical. This report 
shows that patients treated with pegylated interferon com-
bined with ribavirin may have irreversible and severe ocu-
lar complications. This study proposes that chronic hepa-
titis C patients treated with pharmacokinetically improved 
pegylated interferon must also be managed with regular 
and exact ophthalmic examinations on an ongoing basis.
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